作者投稿
专家审稿
编辑办公
邮件订阅
RSS
Real World Research: Bridging the Gap Between Clinical Practice Guidelines and Clinical Decision Making
-
摘要: 临床实践指南是制订临床决策的重要依据，但仍存在诸多因素导致医生无法遵循指南，其中一个重要因素为指南的外部有效性受限，最终使得指南无法为临床决策的制订提供足够依据，此为指南与临床决策之间的距离。真实世界研究可增强指南的外部有效性，为临床决策的制订提供依据，为指南提供本土化证据、成本效益及其他方面相关证据，同时可监测指南的实施，弥补传统指南的证据不足，有助于弥合指南与临床决策之间的距离。在指南制订过程中，可考虑纳入高质量的真实世界研究和真实世界证据，以促进指南优化，助力指南质量提升。Abstract: Clinical practice guidelines are an important basis for clinical decision-making, but there are still many factors that prevent physicians from following the guidelines. One of the problems, the limited external validity of the guidelines, ultimately prevents the guidelines from providing an adequate basis for clinical decision-making, thus forming the gap between the guidelines and clinical decisions. Real-world research can enhance the external validity of the guidelines, provide a basis for clinical decision-making, and offer localized evidence for the guidelines, evidence of cost-effectiveness and other evidence for the guidelines. It can also monitor the implementation of the guidelines and help to make up for the lack of evidence in the formulation of traditional guidelines. Therefore, high-quality real-world studies and real-world evidence may be considered in the guideline development process to facilitate guideline optimization and serve as an aid to guideline quality improvement.
-
Key words:
- real-world study /
- real-world evidence /
- clinical practice guidelines /
- external validity
作者贡献：施秀青负责起草及撰写论文；阎思宇负责确定论文大纲并修订论文；黄桥负责提供修改意见并制作图片；李绪辉、王永博负责提供修改意见；马文昊负责提供写作素材；商洪才负责提出观点并统筹论文；靳英辉负责提出观点并统筹、修订论文。利益冲突：所有作者均声明不存在利益冲突 -
表 1 RWS弥补传统RCT不足、提供临床决策支持的实例
类别 传统RCT不足之处 RWS提供临床决策支持，显示良好的外部有效性 性别 哌柏西利的RCT未纳入男性乳腺癌患者 辉瑞公司利用上市后报告和电子健康记录的额外支持性数据，使得美国FDA批准哌柏西利用于联合芳香酶抑制剂或氟维司群治疗男性激素受体阳性、人表皮生长因子受体2阴性晚期或转移性乳腺癌患者[31] 种族 多发性硬化的RCT普遍缺少黑色人种/非裔美国人的参与，因此缺乏此类人群的最佳治疗证据[32] 基于ESTEEM的RWS研究发现，富马酸二甲酯治疗多发性硬化的疗效在黑色人种/非裔美国人与非黑色人种/非非裔美国人一致[33] 年龄 苯达莫司汀单药或联合利妥昔单抗治疗慢性淋巴细胞白血病老年患者的疗效和耐受性尚不明确 德国的一项大型RWS显示，苯达莫司汀单药或联合利妥昔单抗对慢性淋巴细胞白血病老年患者具有良好的疗效和耐受性[34] 既往史/个人史/依从性 RCT研究NovelSTART[35]旨在探讨短效β2受体激动剂作为哮喘的唯一治疗疗效，其排除标准包括：进入研究前12个月因哮喘入院的患者、每年吸烟20包以上者、40岁以后出现呼吸道症状的现吸烟者或有≥10包烟史的前吸烟者；不愿或不能从目前的哮喘治疗方案中转换的患者等 Salford肺部研究[11]纳入大量真实世界环境下的哮喘或COPD患者，不通过既往史、个人史、合并症及依从性排除患者。该研究结果与RCT一致，每日1次应用吸入性皮质类固醇糠酸氟替卡松与长效β2受体激动剂维兰特罗相结合的干粉吸入剂常规治疗相比，在减少COPD病情恶化方面更具优势[36] 个人史、合并症 RCT研究Wisdom[37]的入组人群为COPD的患者，其排除标准包括：过去几年有严重酗酒或药物滥用史；患有重大疾病(如恶性肿瘤等)；有肺切除的开胸手术史；有哮喘史且需口服或吸入皮质类固醇治疗等10余项内容 BRONCHIOLE trial(Clinical Trials.gov, No.NCT03566667)旨在研究β受体阻断剂治疗对于无明显合并心血管疾病的COPD患者益处的实效性，其排除标准仅包括：现有的心血管疾病、基线时使用β受体阻滞剂治疗、合并β受体阻滞剂的禁忌证，如未经治疗的房室传导阻滞或严重哮喘 RWS：真实世界研究；RCT：随机对照试验；FDA：食品药品监督管理局；COPD：慢性阻塞性肺疾病 
下载: 导出CSV
-
[1] Institute of Medicine. Clinical Practice Guidelines We Can Trust[M]. Washington DC: National Academies Press, 2011. [2] U.S. Food and Drug Administration. Framework for FDA's Real-World Evidence Program[EB/OL]. (2018-12)[2022-04-15]. https://www.fda.gov/media/120060/download .[3] Concato J, Corrigan-Curay J. Real-World Evidence-Where Are We Now?[J]. N Engl J Med, 2022, 386: 1680-1682. doi: 10.1056/NEJMp2200089 [4] U.S. Food and Drug Administration. Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices-Guidance for Industry and Food and Drug Administration Staff[EB/OL]. (2017-08)[2022-04-15]. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-real-world-evidence-support-regulatory-decision-making-medical-devices .[5] 国家药品监督管理局. 真实世界数据用于医疗器械临床评价技术指导原则(征求意见稿)[EB/OL]. (2019-12-13)[2022-04-15]. https://www.cmde.org.cn//zhuanti/zqyj/20191213150200919.html .[6] 国家药品监督管理局. 真实世界证据支持药物研发与审评的指导原则(试行)[EB/OL]. (2020-01-07)[2022-04-15]. https://www.nmpa.gov.cn/xxgk/ggtg/qtggtg/20200107151901190.html .[7] U.S. Food and Drug Administration. 21st Century Cure Act[EB/OL]. (2016-12-13)[2022-04-15]. https://www.fda.gov/regulatory-information/selected-amendments-fdc-act/21st-century-cures-act .[8] U.S. Food and Drug Administration. Submitting Documents Using Real-World Data and Real-World Evidence to FDA for Drugs and Biologics Guidance for Industry[EB/OL]. (2019-05-09)[2022-04-15]. https://www.fda.gov/news-events/fda-brief/fda-brief-fda-issues-draft-guidance-industry-submitting-real-world-evidence-new-drug-and-biologic .[9] 国家药品监督管理局. 国家药监局药审中心关于发布《真实世界研究支持儿童药物研发与审评的技术指导原则(试行)》的通告(2020年第22号)[EB/OL]. (2020-09-01)[2022-04-15]. https://www.nmpa.gov.cn/xxgk/ggtg/qtggtg/20200901104448101.html .[10] Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-World Evidence-What Is It and What Can It Tell Us?[J]. N Engl J Med, 2016, 375: 2293-2297. doi: 10.1056/NEJMsb1609216 [11] New JP, Bakerly ND, Leather D, et al. Obtaining real-world evidence: the Salford Lung Study[J]. Thorax, 2014, 69: 1152-1154. doi: 10.1136/thoraxjnl-2014-205259 [12] Alonso-Coello P, Irfan A, Solà I, et al. The quality of clinical practice guidelines over the last two decades: a systematic review of guideline appraisal studies[J]. Qual Saf Health Care, 2010, 19: e58. [13] Babjuk M, Burger M, Capoun O, et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ)[J]. Eur Urol, 2022, 81: 75-94. doi: 10.1016/j.eururo.2021.08.010 [14] Chang SS, Boorjian SA, Chou R, et al. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline[J]. J Urol, 2016, 196: 1021-1029. doi: 10.1016/j.juro.2016.06.049 [15] Mori K, Miura N, Babjuk M, et al. Low compliance to guidelines in nonmuscle-invasive bladder carcinoma: A systematic review[J]. Urol Oncol, 2020, 38: 774-782. doi: 10.1016/j.urolonc.2020.06.013 [16] Chamie K, Saigal CS, Lai J, et al. Compliance with guidelines for patients with bladder cancer: variation in the delivery of care[J]. Cancer, 2011, 117: 5392-5401. doi: 10.1002/cncr.26198 [17] Posen A, Benken S, Kaluzna SD, et al. Poor guideline adherence in a real-world evaluation of hypertensive emergency management[J]. Am J Emerg Med, 2022, 51: 46-52. doi: 10.1016/j.ajem.2021.09.073 [18] Cabana MD, Rand CS, Powe NR, et al. Why don't physicians follow clinical practice guidelines? A framework for improvement[J]. JAMA, 1999, 282: 1458-1465. doi: 10.1001/jama.282.15.1458 [19] Jin YH, Tan LM, Khan KS, et al. Determinants of successful guideline implementation: a national cross-sectional survey[J]. BMC Med Inform Decis Mak, 2021, 21: 19. doi: 10.1186/s12911-020-01382-w [20] Wong GW, Miravitlles M, Chisholm A, et al. Respiratory guidelines——which real world?[J]. Ann Am Thorac Soc, 2014, 11: S85-S91. doi: 10.1513/AnnalsATS.201309-298RM [21] Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations[J]. BMJ, 2008, 336: 924-926. doi: 10.1136/bmj.39489.470347.AD [22] Herland K, Akselsen JP, Skjønsberg OH, et al. How representative are clinical study patients with asthma or COPD for a larger "real life" population of patients with obstructive lung disease?[J]. Respir Med, 2005, 99: 11-19. doi: 10.1016/j.rmed.2004.03.026 [23] Hoffman SN, TenBrook JA, Wolf MP, et al. A meta-analysis of randomized controlled trials comparing coronary artery bypass graft with percutaneous transluminal coronary angioplasty: one-to eight-year outcomes[J]. J Am Coll Cardiol, 2003, 41: 1293-1304. doi: 10.1016/S0735-1097(03)00157-8 [24] Brett W, Hirschmann MT, Guller U, et al. CABG vs. PCI in coronary artery disease: what is the evidence?[J]. Card Surg Today, 2006, 2: 43-55. [25] Grapow MT, von Wattenwyl R, Guller U, et al. Rando-mized controlled trials do not reflect reality: real-world analyses are critical for treatment guidelines![J]. J Thorac Cardiovasc Surg, 2006, 132: 5-7. doi: 10.1016/j.jtcvs.2006.03.035 [26] Kennedy-Martin T, Curtis S, Faries D, et al. A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results[J]. Trials, 2015, 16: 495. doi: 10.1186/s13063-015-1023-4 [27] Chew SY, Koh MS, Loo CM, et al. Making Clinical Practice Guidelines Pragmatic: How Big Data and Real World Evidence Can Close the Gap[J]. Ann Acad Med Singap, 2018, 47: 523-527. doi: 10.47102/annals-acadmedsg.V47N12p523 [28] Hayward RS. Clinical practice guidelines on trial[J]. CMAJ, 1997, 156: 1725-1727. [29] 周奇, 董冲亚, 王业明, 等. 循证医学理念在指导临床研究与实践中的作用: 基于对抗病毒药物治疗新型冠状病毒肺炎的思考[J]. 中国循证医学杂志, 2022, 22: 373-379. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXZ202204001.htm [30] Schneeweiss S, Patorno E. Conducting Real-world Evidence Studies on the Clinical Outcomes of Diabetes Treatments[J]. Endocr Rev, 2021, 42: 658-690. doi: 10.1210/endrev/bnab007 [31] Wedam S, Fashoyin-Aje L, Bloomquist E, et al. FDA Approval Summary: Palbociclib for Male Patients with Metastatic Breast Cancer[J]. Clin Cancer Res, 2020, 26: 1208-1212. doi: 10.1158/1078-0432.CCR-19-2580 [32] Khan O, Williams MJ, Amezcua L, et al. Multiple sclerosis in US minority populations: Clinical practice insights[J]. Neurol Clin Pract, 2015, 5: 132-142. doi: 10.1212/CPJ.0000000000000112 [33] Williams MJ, Amezcua L, Okai A, et al. Real-World Safety and Effectiveness of Dimethyl Fumarate in Black or African American Patients with Multiple Sclerosis: 3-Year Results from ESTEEM[J]. Neurol Ther, 2020, 9: 483-493. doi: 10.1007/s40120-020-00193-5 [34] Kleeberg UR, Linde H, Günther G, et al. Bendamustin-Rituximab Combination Is a Safe and Effective, Ambulatory Treatment for Elderly Patients with Chronic Lymphocytic Leukemia: Retrospective Real-world Analysis by Age from a German Registry and Review of the Literature[J]. Anticancer Res, 2016, 36: 2827-2838. [35] Beasley R, Holliday M, Reddel HK, et al. Controlled Trial of Budesonide-Formoterol as Needed for Mild Asthma[J]. N Engl J Med, 2019, 380: 2020-2030. doi: 10.1056/NEJMoa1901963 [36] Albertson TE, Murin S, Sutter ME, et al. The Salford Lung Study: a pioneering comparative effectiveness approach to COPD and asthma in clinical trials[J]. Pragmat Obs Res, 2017, 8: 175-181. [37] Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD[J]. N Engl J Med, 2014, 371: 1285-1294. doi: 10.1056/NEJMoa1407154 [38] Chen Y, Wang C, Shang H, et al. Clinical practice guidelines in China[J]. BMJ, 2018, 360: j5158. [39] Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines[J]. Chest, 2012, 141: e419S-e496S. doi: 10.1378/chest.11-2301 [40] Konstantinides SV, Torbicki A, Agnelli G, et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism[J]. Eur Heart J, 2014, 35: 3033-3069. doi: 10.1093/eurheartj/ehu283 [41] Wang C, Zhai Z, Yang Y, et al. Efficacy and safety of low dose recombinant tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism: a randomized, multicenter, controlled trial[J]. Chest, 2010, 137: 254-262. doi: 10.1378/chest.09-0765 [42] Franklin JM, Glynn RJ, Martin D, et al. Evaluating the Use of Nonrandomized Real-World Data Analyses for Regulatory Decision Making[J]. Clin Pharmacol Ther, 2019, 105: 867-877. doi: 10.1002/cpt.1351 [43] 彭晓霞, 舒啸尘, 谭婧, 等. 基于真实世界数据评价治疗结局的观察性研究设计技术规范[J]. 中国循证医学杂志, 2019, 19: 779-786. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXZ201907004.htm [44] Cortese S, Panei P, Arcieri R, et al. Safety of Methylphenidate and Atomoxetine in Children with Attention-Deficit/Hyperactivity Disorder (ADHD): Data from the Italian National ADHD Registry[J]. CNS Drugs, 2015, 29: 865-877. doi: 10.1007/s40263-015-0266-7 [45] 谭婧, 刘兴会, 孙鑫. 基于真实世界数据的疾病管理研究[J]. 协和医学杂志, 2019, 10: 284-288. doi: 10.3969/j.issn.1674-9081.2019.03.017 [46] Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association[J]. Eur Heart J, 2012, 33: 2719-2747. doi: 10.1093/eurheartj/ehs253 [47] Andrade AA, Li J, Radford MJ, et al. Clinical Benefit of American College of Chest Physicians versus European Society of Cardiology Guidelines for Stroke Prophylaxis in Atrial Fibrillation[J]. J Gen Intern Med, 2015, 30: 777-782. doi: 10.1007/s11606-015-3201-1 [48] Quanstrum KH, Hayward RA. Lessons from the mammography wars[J]. N Engl J Med, 2010, 363: 1076-1079. doi: 10.1056/NEJMsb1002538 [49] Shaughnessy AF, Cosgrove L, Lexchin JR. The Need to Systematically Evaluate Clinical Practice Guidelines[J]. J Am Board Fam Med, 2016, 29: 644-648. doi: 10.3122/jabfm.2016.06.160115 [50] Steels S, van der Zande M, van Staa TP. The role of real-world data in the development of treatment guidelines: a case study on guideline developers' opinions about using observational data on antibiotic prescribing in primary care[J]. BMC Health Serv Res, 2019, 19: 942. doi: 10.1186/s12913-019-4787-5 [51] National Institue for Health and Care Excellence. NICE strategy 2021 to 2026-Dynamic, Collaborative, Excellent[EB/OL]. (2021-04)[2022-04-15]. https://www.nice.org.uk/about/who-we-are/corporate-publications/the-nice-strategy-2021-to-2026 .[52] Collins R, Bowman L, Landray M, et al. The Magic of Randomization versus the Myth of Real-World Evidence[J]. N Engl J Med, 2020, 382: 674-678. doi: 10.1056/NEJMsb1901642 [53] Levy RI. Currently available lipid-lowering agents[J]. Hosp Pract (Off Ed), 1988, 23: 14-21. doi: 10.1080/21548331.1988.11703634 [54] Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy[J]. Lancet, 2016, 388: 2532-2561. doi: 10.1016/S0140-6736(16)31357-5 [55] Rimm EB, Stampfer MJ, Ascherio A, et al. Vitamin E consumption and the risk of coronary heart disease in men[J]. N Engl J Med, 1993, 328: 1450-1456. doi: 10.1056/NEJM199305203282004 [56] Stampfer MJ, Hennekens CH, Manson JE, et al. Vitamin E consumption and the risk of coronary disease in women[J]. N Engl J Med, 1993, 328: 1444-1449. doi: 10.1056/NEJM199305203282003 [57] Heart Outcomes Prevention Evaluation Study Investigators, Yusuf S, Dagenais G, et al. Vitamin E supplementation and cardiovascular events in high-risk patients[J]. N Engl J Med, 2000, 342: 154-160. doi: 10.1056/NEJM200001203420302 [58] 刘晓清, 孙晓川. 真实世界证据[J]. 协和医学杂志, 2017, 8: 305-310. doi: 10.3969/j.issn.1674-9081.2017.05.021 [59] Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy[J]. JAMA, 2003, 290: 1624-1632. [60] 孙鑫, 谭婧, 唐立, 等. 基于真实世界证据的上市后药品评价技术框架体系: 思考与建议[J]. 中国循证医学杂志, 2018, 18: 277-283. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXZ201804003.htm [61] 谭婧, 程亮亮, 王雯, 等. 患者登记研究的策划与患者登记数据库构建: 基于观察性设计的真实世界研究[J]. 中国循证医学杂志, 2017, 17: 1365-1372. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXZ201712001.htm [62] 唐立, 康德英, 喻佳洁, 等. 实效性随机对照试验: 真实世界研究的重要设计[J]. 中国循证医学杂志, 2017, 17: 999-1004. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXZ201709002.htm [63] Booth CM, Karim S, Mackillop WJ. Real-world data: towards achieving the achievable in cancer care[J]. Nat Rev Clin Oncol, 2019, 16: 312-325. [64] 徐浩, 史大卓, 刘保延, 等. 以临床实践数据为导向构建中西医结合临床指南的设想[J]. 中国中西医结合杂志, 2009, 29: 544-547. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXJ200906023.htm [65] 王雯, 刘艳梅, 谭婧, 等. 回顾性数据库研究的概念、策划与研究数据库构建[J]. 中国循证医学杂志, 2018, 18: 230-237. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXZ201802016.htm -
点击查看大图
图(1) / 表(1)
计量
- 文章访问数: 449
- HTML全文浏览量: 81
- PDF下载量: 100
- 被引次数: 0
